Skip to content

Study · Measured the body's own peptide · 1998

3 results

A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499).

Van de Kar LD, Levy AD, Li Q, Brownfield MS

Pharmacology, biochemistry, and behavior1 Jul 1998Cited by 15 (Europe PMC)

PMID9678651 (opens in a new tab)DOI10.1016/s0091-3057(98)00025-2 (opens in a new tab)PepBankPUB-09678651
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In conscious male rats, the 5-HT1A agonist alnespirone increased secretion of the body's own oxytocin in a dose-dependent manner, with maximal effect 15 min after 5 mg/kg i.p.

    In plain wordsIn rats, the drug alnespirone raised the body's own oxytocin levels in a dose-dependent way.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin response to alnespirone
    Study

    ratn: not reported in source

    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    The dose-response and time-course effects on the secretion of oxytocin and vasopressin revealed that alnespirone stimulated oxytocin in a dose-dependent manner
    2 context sentences
    Summary · context
    Time of maximal effect following injection of alnespirone (5 mg/kg, i.p.) was as early as 15 min postinjection, with significant stimulation persisting for 30 min.
    Summary · context
    The effect of the serotonin1A (5-HT1A) agonist alnespirone (S-20499) on the secretion of both oxytocin and vasopressin was examined in the same conscious, unrestrained male rats.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In male rats, pretreatment with pindolol shifted the alnespirone dose-response curve to the right and inhibited the alnespirone-induced rise in plasma oxytocin.

    In plain wordsIn rats, pindolol blocked the rise in the body's own oxytocin caused by alnespirone.

    Peptide
    Oxytocin
    Outcome
    DecreaseEffect of pindolol on alnespirone-induced oxytocin rise
    Study

    ratn: not reported in source

    Comparator
    Alnespirone alone
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Pretreatment with a low dose of the 5-HT1A/beta-adrenoceptor antagonist (-)-pindolol (0.3 mg/kg, s.c.), 30 min prior to injection of alnespirone (0, 2, 5, and 10 mg/kg, i.p.) shifted the dose-response curve to the right and inhibited the effect of alnespirone on plasma oxytocin concentration.
    1 context sentence
    Summary · context
    The effect of the serotonin1A (5-HT1A) agonist alnespirone (S-20499) on the secretion of both oxytocin and vasopressin was examined in the same conscious, unrestrained male rats.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In male rats, pretreatment with spiperone dose-dependently shifted the alnespirone dose-response curve for the body's own oxytocin to the right.

    In plain wordsIn rats, spiperone reduced the rise in the body's own oxytocin caused by alnespirone.

    Peptide
    Oxytocin
    Outcome
    DecreaseEffect of spiperone on alnespirone-induced oxytocin rise
    Study

    ratn: not reported in source

    Comparator
    Alnespirone alone
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Furthermore, pretreatment with a low or a high dose of the 5-HT1A/2A/dopamine D2 antagonist spiperone (0.01 or 3 mg/kg, s.c.) dose dependently shifted the alnespirone dose-response curve effect of alnespirone to the right.
    1 context sentence
    Summary · context
    The effect of the serotonin1A (5-HT1A) agonist alnespirone (S-20499) on the secretion of both oxytocin and vasopressin was examined in the same conscious, unrestrained male rats.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.